However, some studies examining activating mutations in NRF2 or loss of function of KEAP1 in human cancers, such as esophagus, skin, and ovarian cancers, did find one or more of these mutations altering the NRF2 pathway, which suggests protumorigenic involvement [24, 25] in these extrapulmonary tissues. The gene discussed is NFE2L2; the disease is ovarian carcinoma.